FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2142675265> ?p ?o ?g. }

• W2142675265 endingPage "345" @default.
• W2142675265 startingPage "339" @default.
• W2142675265 abstract "Single-agent cetuximab is safe and active in elderly patients with advanced colorectal cancer (CRC). A cetuximab-capecitabine combination has not previously been tested in elderly patients with advanced CRC.Sixty-six patients with advanced CRC were treated with cetuximab as a 400 mg/m2 i.v. infusion followed by 250 mg/m2 i.v. weekly plus capecitabine at a dose of 1,250 mg/m2 every 12 hours. After the inclusion of 27 patients, the protocol was amended for safety reasons, reducing the dose of capecitabine to 1,000 mg/m2 every 12 hours. Thirty-nine additional patients were treated with the reduced dose of capecitabine.The overall response rate was 31.8%. KRAS status was determined in 58 patients (88%). Fourteen of 29 patients with wild-type KRAS tumors responded (48.3%; 95% confidence interval [CI], 29.4%-67.5%), compared with six of 29 patients with mutant KRAS tumors (20.7%; 95% CI, 8.0%-39.7%). The median progression-free survival (PFS) interval was 7.1 months. The median PFS interval for patients whose tumors were wild-type KRAS was significantly longer than for those with mutant KRAS tumors (8.4 months versus 6.0 months; p = .024). The high incidence of severe paronychia (29.6%) declined (7.7%) after capecitabine dose adjustment.Cetuximab plus capecitabine at a dose of 1,000 mg/m2 every 12 hours may be an alternative to more aggressive regimens in elderly patients with advanced wild-type KRAS CRC." @default.
• W2142675265 created "2016-06-24" @default.
• W2142675265 creator A5003707413 @default.
• W2142675265 creator A5007291981 @default.
• W2142675265 creator A5013884017 @default.
• W2142675265 creator A5030215661 @default.
• W2142675265 creator A5036588901 @default.
• W2142675265 creator A5054498659 @default.
• W2142675265 creator A5073742272 @default.
• W2142675265 creator A5074210261 @default.
• W2142675265 creator A5085058149 @default.
• W2142675265 creator A5086660695 @default.
• W2142675265 creator A5087769668 @default.
• W2142675265 date "2012-02-23" @default.
• W2142675265 modified "2023-10-01" @default.
• W2142675265 title "First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to<i>KRAS</i>Status from a Spanish TTD Group Study" @default.
• W2142675265 cites W1927441390 @default.
• W2142675265 cites W1971109416 @default.
• W2142675265 cites W1979706544 @default.
• W2142675265 cites W1993517991 @default.
• W2142675265 cites W2011968380 @default.
• W2142675265 cites W2018991771 @default.
• W2142675265 cites W2084330540 @default.
• W2142675265 cites W2102601598 @default.
• W2142675265 cites W2114509795 @default.
• W2142675265 cites W2118059295 @default.
• W2142675265 cites W2125942839 @default.
• W2142675265 cites W2127500959 @default.
• W2142675265 cites W2134142320 @default.
• W2142675265 cites W2139168548 @default.
• W2142675265 cites W2142564546 @default.
• W2142675265 cites W2145070131 @default.
• W2142675265 cites W2145188374 @default.
• W2142675265 cites W2152059306 @default.
• W2142675265 cites W2162315065 @default.
• W2142675265 cites W2166112130 @default.
• W2142675265 cites W2329773368 @default.
• W2142675265 cites W2331849216 @default.
• W2142675265 cites W2409420104 @default.
• W2142675265 cites W242688370 @default.
• W2142675265 cites W2887955879 @default.
• W2142675265 cites W39360429 @default.
• W2142675265 cites W4385789423 @default.
• W2142675265 doi "https://doi.org/10.1634/theoncologist.2011-0406" @default.
• W2142675265 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3316919" @default.
• W2142675265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22363067" @default.
• W2142675265 hasPublicationYear "2012" @default.
• W2142675265 type Work @default.
• W2142675265 sameAs 2142675265 @default.
• W2142675265 citedByCount "70" @default.
• W2142675265 countsByYear W21426752652012 @default.
• W2142675265 countsByYear W21426752652013 @default.
• W2142675265 countsByYear W21426752652014 @default.
• W2142675265 countsByYear W21426752652015 @default.
• W2142675265 countsByYear W21426752652016 @default.
• W2142675265 countsByYear W21426752652017 @default.
• W2142675265 countsByYear W21426752652018 @default.
• W2142675265 countsByYear W21426752652019 @default.
• W2142675265 countsByYear W21426752652020 @default.
• W2142675265 countsByYear W21426752652021 @default.
• W2142675265 countsByYear W21426752652022 @default.
• W2142675265 countsByYear W21426752652023 @default.
• W2142675265 crossrefType "journal-article" @default.
• W2142675265 hasAuthorship W2142675265A5003707413 @default.
• W2142675265 hasAuthorship W2142675265A5007291981 @default.
• W2142675265 hasAuthorship W2142675265A5013884017 @default.
• W2142675265 hasAuthorship W2142675265A5030215661 @default.
• W2142675265 hasAuthorship W2142675265A5036588901 @default.
• W2142675265 hasAuthorship W2142675265A5054498659 @default.
• W2142675265 hasAuthorship W2142675265A5073742272 @default.
• W2142675265 hasAuthorship W2142675265A5074210261 @default.
• W2142675265 hasAuthorship W2142675265A5085058149 @default.
• W2142675265 hasAuthorship W2142675265A5086660695 @default.
• W2142675265 hasAuthorship W2142675265A5087769668 @default.
• W2142675265 hasBestOaLocation W21426752651 @default.
• W2142675265 hasConcept C121608353 @default.
• W2142675265 hasConcept C126322002 @default.
• W2142675265 hasConcept C143998085 @default.
• W2142675265 hasConcept C2777909004 @default.
• W2142675265 hasConcept C2779998722 @default.
• W2142675265 hasConcept C2781187634 @default.
• W2142675265 hasConcept C526805850 @default.
• W2142675265 hasConcept C71924100 @default.
• W2142675265 hasConcept C90924648 @default.
• W2142675265 hasConceptScore W2142675265C121608353 @default.
• W2142675265 hasConceptScore W2142675265C126322002 @default.
• W2142675265 hasConceptScore W2142675265C143998085 @default.
• W2142675265 hasConceptScore W2142675265C2777909004 @default.
• W2142675265 hasConceptScore W2142675265C2779998722 @default.
• W2142675265 hasConceptScore W2142675265C2781187634 @default.
• W2142675265 hasConceptScore W2142675265C526805850 @default.
• W2142675265 hasConceptScore W2142675265C71924100 @default.
• W2142675265 hasConceptScore W2142675265C90924648 @default.
• W2142675265 hasFunder F4320311647 @default.
• W2142675265 hasIssue "3" @default.
• W2142675265 hasLocation W21426752651 @default.
• W2142675265 hasLocation W21426752652 @default.
• W2142675265 hasLocation W21426752653 @default.

• next